Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01433991 | A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) | terminated | Phase 1 / Phase 2 | 30 | Eisai Inc.INDUSTRY | 1 | Jun 8, 2021 | clinicaltrials |
| NCT04162301 | A Study of CS3002 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 10 | CStone PharmaceuticalsINDUSTRY | 1 | Apr 15, 2021 |
| clinicaltrials |
| NCT03264092 | Comparison of Three Tissue Acquiring Techniques During EUS Guided Biopsies of Solid Tumors. | terminated | N/A | 55 | Texas Tech University Health Sciences Center, El PasoOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT01981187 | LGX818 for Patients With BRAFV600 Mutated Tumors(SIGNATURE) | terminated | Phase 2 | 12 | PfizerINDUSTRY | 1 | Mar 26, 2021 | clinicaltrials |
| NCT03992326 | Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors | terminated | Phase 1 | 6 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT03134638 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 107 | Syros PharmaceuticalsINDUSTRY | 3 | Mar 9, 2021 | clinicaltrials |
| NCT03600467 | Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma(START) | terminated | Phase 2 | 4 | St Vincent's Hospital, SydneyOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT03721679 | Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 | terminated | Phase 1 / Phase 2 | 7 | Oncovir, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02587962 | Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors | terminated | Phase 1 / Phase 2 | 34 | MedivirINDUSTRY | 1 | Jan 14, 2021 | clinicaltrials |
| NCT02608125 | A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma | terminated | Phase 1 | 45 | Principia Biopharma, a Sanofi CompanyINDUSTRY | 2 | Dec 24, 2020 | clinicaltrials |
| NCT03096340 | Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer | terminated | Phase 1 | 10 | Intezyne Technologies, Inc.INDUSTRY | 1 | Dec 22, 2020 | clinicaltrials |
| NCT01529307 | First in Human Trial of TAS266 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 6 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01064089 | Dose Escalation of HSP990 in Japan/Korea | terminated | Phase 1 | 17 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01190241 | Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study(TSAP) | terminated | N/A | 45 | Amsterdam UMC, location VUmcOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT03976050 | Phase I Study of HL-085 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 4 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | Nov 18, 2020 | clinicaltrials |
| NCT01987596 | Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer | terminated | Phase 3 | 23 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 29, 2020 | clinicaltrials |
| NCT02253992 | An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 232 | Bristol-Myers SquibbINDUSTRY | 4 | Oct 5, 2020 | clinicaltrials |
| NCT02476955 | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | terminated | Phase 1 | 41 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Sep 30, 2020 | clinicaltrials |
| NCT00726830 | Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer | terminated | N/A | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01948297 | Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations | terminated | Phase 1 | 77 | Debiopharm International SAINDUSTRY | 5 | Sep 9, 2020 | clinicaltrials |
| NCT03539484 | A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors | terminated | Phase 1 | 26 | Hoffmann-La RocheINDUSTRY | 4 | Sep 3, 2020 | clinicaltrials |
| NCT01369433 | A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols | terminated | N/A | 225 | AVEO Pharmaceuticals, Inc.INDUSTRY | 6 | Sep 1, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03511222 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | terminated | Phase 1 | 16 | Washington University School of MedicineOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT03256331 | Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients | terminated | Phase 1 | 23 | Belx Bio-Pharmaceutical (Taiwan) CorporationINDUSTRY | 1 | Jun 1, 2020 | clinicaltrials |
| NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors(D-1MT) | terminated | Phase 1 | 17 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02648711 | Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors | terminated | Phase 1 | 41 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03361228 | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 5 | Incyte CorporationINDUSTRY | 1 | May 21, 2020 | clinicaltrials |
| NCT03700294 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | terminated | Phase 1 | 18 | ADC Therapeutics S.A.INDUSTRY | 1 | May 1, 2020 | clinicaltrials |
| NCT01548924 | Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors | terminated | Phase 1 | 13 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Apr 17, 2020 | clinicaltrials |
| NCT02265510 | An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 83 | Incyte CorporationINDUSTRY | 1 | Apr 17, 2020 | clinicaltrials |
| NCT01358331 | A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) | terminated | Phase 1 | 25 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 2, 2020 | clinicaltrials |
| NCT03680560 | Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers | terminated | Phase 1 | 6 | Cogent Biosciences, Inc.INDUSTRY | 1 | Mar 31, 2020 | clinicaltrials |
| NCT02082626 | Study of Eribulin in Children With Cancer to Determine Safety(ERIBULIN) | terminated | Phase 1 | 3 | University of OklahomaOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02541604 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | Hoffmann-La RocheINDUSTRY | 11 | Feb 25, 2020 | clinicaltrials |
| NCT01557881 | Positron Emission Tomography/Magnetic Resonance Imaging in Patients | terminated | N/A | 98 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT02678754 | Caris Molecular Intelligence Registry(CMIR) | terminated | — | 4,981 | Caris Science, Inc.INDUSTRY | 0 | Jan 23, 2020 | clinicaltrials |
| NCT02620839 | Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies | terminated | Phase 1 | 28 | Pamela MunsterOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT00582816 | Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors | terminated | Phase 1 / Phase 2 | 9 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT01163071 | A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas | terminated | Phase 1 | 60 | CelgeneINDUSTRY | 1 | Nov 14, 2019 | clinicaltrials |
| NCT02553499 | Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) | terminated | Phase 1 | 37 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 4, 2019 | clinicaltrials |
| NCT02950103 | Efficacy and Safety of Synthetic Phosphoethanolamine in Solid Tumor Patients | terminated | Phase 2 | 73 | Secretaria de Estado da SaúdeOTHER_GOV | 1 | Sep 30, 2019 | clinicaltrials |
| NCT02559492 | Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors | terminated | Phase 1 | 142 | Incyte CorporationINDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT02979392 | Phase I Study of TENPA in Advanced Solid Cancer | terminated | Phase 1 | 19 | Yung-Jue BangOTHER | 1 | Sep 25, 2019 | clinicaltrials |
| NCT03182257 | Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors(ONTRK) | terminated | Phase 1 | 1 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 2 | Sep 13, 2019 | clinicaltrials |
| NCT03427073 | A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours | terminated | Phase 1 | 20 | Almac DiscoveryINDUSTRY | 1 | Sep 11, 2019 | clinicaltrials |
| NCT01065805 | A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma | terminated | Phase 1 / Phase 2 | 94 | AHS Cancer Control AlbertaOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT02737072 | A Study of LY2510924 and Durvalumab in Participants With Solid Tumors | terminated | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 0 | Aug 12, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2021source: clinicaltrials